topics / glp-1
Tagged glp-1.
- Strong human CagriSema An investigational once-weekly fixed combination of cagrilintide (an amylin analog) plus semaglutide (a GLP-1 drug) with large peer-reviewed Phase 3 weight-loss data, but no approval yet and a failed head-to-head against tirzepatide.
- Preliminary human Ecnoglutide A long-acting, cAMP-biased GLP-1 receptor agonist approved in China for type 2 diabetes and weight management, with genuine peer-reviewed Phase 3 data that is still confined to Chinese populations and not FDA-approved.
- Strong human Liraglutide (Victoza / Saxenda): An Evidence Review A once-daily GLP-1 drug with large RCT support for glucose control, weight loss, and lower cardiovascular risk in high-risk type 2 diabetes.
- Preliminary human Mazdutide: real Phase 3 data, but almost all of it from China A GLP-1/glucagon dual agonist approved in China for weight loss and diabetes, with genuine RCT evidence that is still sponsor-funded and single-country.
- Preliminary human Retatrutide An investigational triple-hormone agonist with striking weight-loss data in trials, but not yet FDA-approved and with no peer-reviewed Phase 3 results.
- Strong human Semaglutide (Ozempic / Wegovy): An Evidence Review A GLP-1 drug with strong RCT evidence for weight loss, glucose control, and cutting cardiovascular events in high-risk patients.
- Preliminary human Survodutide: Strong Phase 2 data and a first Phase 3 readout, but still investigational An investigational GLP-1/glucagon dual agonist with solid placebo-controlled Phase 2 trials and one positive Phase 3 topline, but no approval and no peer-reviewed Phase 3 data.
- Strong human Tirzepatide (Mounjaro / Zepbound) A dual GIP/GLP-1 receptor agonist with strong RCT evidence for type 2 diabetes, weight loss, and sleep apnea; GI side effects are common.